Loading...
•
Jun 30, 2021
Evolent Health Q2 2021 Earnings Report
Evolent Health's Q2 2021 performance reflected revenue increase, strategic acquisitions, and raised full-year guidance.
Key Takeaways
Evolent Health announced its Q2 2021 financial results with a revenue of $222.1 million, a net loss of $(9.1) million, and an adjusted EBITDA of $13.3 million. The company has raised its full-year 2021 guidance. They also entered into an agreement to acquire Vital Decisions and added new provider partnerships.
GAAP revenue reached $222.1 million, a 2.2% increase year-over-year.
Net loss attributable to common shareholders was $(9.1) million.
Adjusted EBITDA increased to $13.3 million from $10.5 million in the prior year.
Total lives managed reached 12.2 million.
Forward Guidance
Evolent Health expects revenue to be in the range of $870 million to $900 million and Adjusted EBITDA to be in the range of $50 million to $58 million for the year ending December 31, 2021. For the third quarter 2021, revenue is expected to be in the range of $215 million to $230 million and Adjusted EBITDA is expected to be in the range of $11 million to $15 million.
Positive Outlook
- Revenue for the year ending December 31, 2021 is expected to be in the range of approximately $870 million to $900 million.
- Previous revenue guidance was $845 million to $880 million.
- Adjusted EBITDA is expected to be in the range of approximately $50 million to $58 million.
- Previous Adjusted EBITDA guidance was $42 million to $52 million.
- For the three months ending September 30, 2021, revenue is expected to be in the range of approximately $215 million to $230 million.
Challenges Ahead
- Adjusted EBITDA is expected to be in the range of approximately $11 million to $15 million for the three months ending September 30, 2021.
- Actual results may differ materially.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...